You are here

Our Pipeline

Our pipeline

What's in the works

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.
Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

Promising science for a range of cancers

Our oncology pipeline includes therapies for a range of cancers, including kidney cancer, breast cancer, gastrointestinal cancer, non-small cell lung cancer, and blood cancers.
We are investigating cancer cell signaling mechanisms and oncogenic drivers, cancer stem cells, mechanisms of drug resistance, and technologies that enable selective drug delivery to tumor tissues. We are also exploring emerging areas of cancer biology, including cancer metabolism and epigenetics.
image

With us, it's personal

When I think of cancer, I don’t think of an amorphous entity. I think of the individual patients it impacts. One of them is my wife. Because of her and millions of others like her, my team and Pfizer are focused on creating a world in which cancer is detected before tumors are formed—both before and after treatment.
— Brion William Murray, PhD
Research Fellow

The transformative power of immuno-oncology

We are building a deep expertise in immuno-oncology, investigating novel ways to activate the immune system and prevent cancer cells from evading the body’s defense mechanisms.
With a broad pipeline of compounds spanning multiple mechanisms of action, Pfizer is uniquely positioned to shape this new revolution that is redefining how we treat cancer and has initiated clinical trials to explore multiple drugs both as single agents and in combinations.

Oncology Pipeline Snapshot as of

  • Discovery Projects
  • Phase 1
    13
  • Phase 2
    5
  • Phase 3
    20
  • Registration
    4
  • Total42
 
Compound Name
Indication
Phase
Submission Type
Compound Type
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Merkel Cell Carcinoma (E.U.), Combo w/ PF-05082566 (41BB) for: Melanoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Triple-Negative Breast Cancer, *Cancer (Biologic) Phase 2 New Molecular Entity Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
2nd Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Non-Small Cell Lung Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Gastric Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
3rd Line Gastric Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Platinum Resistant/Refractory Ovarian Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Ovarian Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Urothelial Cancer (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
1st Line Renal Cell Carcinoma (Biologic) (Combo w/ Inlyta (axitinib)) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Biologic) Phase 3 Product Enhancement Biologic
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
2nd Line Metastatic Merkel Cell Carcinoma (E.U.) (Biologic) Registration New Molecular Entity Biologic
Bosulif (bosutinib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Abl and src-family Kinase Inhibitor
Go to clinical trial
1st Line Chronic Myelogenous Leukemia (ORPHAN - U.S.) Phase 3 Product Enhancement Small Molecule
dacomitinib (PF-00299804)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
pan-HER Inhibitor
Go to clinical trial
1st Line EGFR-activating mutant Non-Small Cell Lung Cancer (ORPHAN - U.S.) Phase 3 New Molecular Entity Small Molecule
gedatolisib (PF-05212384)
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Phosphatidyl inositol-3 kinase catalytic sub-unit a inhibitor / mammalian target of rapamycin inhibitor (PI3K/mTOR)
Go to clinical trial
Cancer Phase 1 New Molecular Entity Small Molecule
glasdegib (PF-04449913)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
SMO (smoothened) antagonist
Go to clinical trial
Acute Myeloid Leukemia, *Cancer Phase 2 New Molecular Entity Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
Squamous Cell Carcinoma of the Head and Neck Phase 2 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
High Risk Early Breast Cancer Phase 3 Product Enhancement Small Molecule
Ibrance (palbociclib)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
CDK 4,6 Kinase Inhibitor
Go to clinical trial
Early Breast Cancer in Adjuvant Setting, *Cancer Phase 3 Product Enhancement Small Molecule